… differential PD-L1 expression … PD-L1, we next performed LCM to isolate breast cancer cells
from primary tumors. Following RNA extraction, qRT-PCR confirmed the presence of PD-L1 …

… , most clinical investigations of PD-1/PD-L1 targeting have been … breast cancer, including
HER2-positive and luminal cancers. … of PD-1/PD-L1-based therapeutics in breast cancer, from …

… PD-1 or PD-L1 with specific antibodies like pembrolizumab or atezulizumab. In breast
cancer, potential response was demonstrated in metastatic triple-negative breast cancers. …

… triple negative breast cancer (mTNBC), if the tumor-associated immune cells express …
other PD-L1 tests are reliable and of clinical value to predict the response of breast cancer …

… association between PD-L1 expression and OS in breast cancer patients… PD-L1 overexpression
was associated with shorter OS in patients with breast cancer than the absence of PD-L1 …

… To assess PD-L1 and PD-L2 expressions, we conducted immunohistochemistry studies
using a breast cancer tissue microarray encompassing a total of 192 breast cancer cases, …

… review is to summarize the data regarding PD-L1 expression in breast cancer and the results
of first clinical trials with PD-1 or PD-L1 inhibitors in patients with metastatic breast cancer. …

… most important aims in the current research in breast immunotherapy. In the present review,
we … (PD-1/PD-L1) in breast cancer and explore the predictive aspects in the PD-L1 testing. …

… correlation between PDL1 tumor expression and responses. We retrospectively analyzed
PDL1 mRNA expression in 45 breast cancer cell lines and 5,454 breast cancers profiled using …

… PD-L1 expression. This study identified a subset of basal breast cancer cells lines with much
higher PD-L1 … Molecular and pathologic data suggests that these high PD-L1 expressing …